Samar AbdAlhamed Tabra, Hany M Aly, Saad Ghanem, Mohammed Hassan Abu-Zaid
{"title":"银屑病关节炎的高尿酸血症:临床相关性和意义。","authors":"Samar AbdAlhamed Tabra, Hany M Aly, Saad Ghanem, Mohammed Hassan Abu-Zaid","doi":"10.1007/s10067-025-07400-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Psoriatic arthritis (PsA) patients may have elevated serum uric acid levels, and hyperuricemia may impact the degree of inflammation and clinical disease severity.</p><p><strong>Objectives: </strong>comparison between PsA patients with and without hyperuricemia and assessment of the effect of hyperuricemia on clinical presentation, disease activity, disease severity, and associated comorbidities in PsA patients.</p><p><strong>Methods: </strong>76 PsA patients with hyperuricemia and 74 PsA patients with normal uric acid as control were included. Demographic, clinical, comorbidities, and laboratory data were collected. Hyperuricemia threshold ≥ 60 mg/L.</p><p><strong>Results: </strong>There were no significant differences between patients with and without hyperuricemia regarding gender, PsA articular subtype, PASI score, and treatment received, while patients with hyperuricemia were older (40.47 ± 8.53 vs 34.59 ± 7.29, p = 0.0001), had more comorbidity, higher body mass index (BMI) (28.49 ± 2.07 vs 26.91 ± 1.63kg/m2, p = 0.0001), DAPSA score (16.75 ± 7.04 vs 9.32 ± 6.35, p = 0.0001), ESR (34.78 ± 7.12 vs 28.55 ± 8.97, p = 0.0001), CRP (11.42 ± 3.23 vs 8.68 ± 4.04, p = 0.0001), serum cholesterol (220.42 ± 46.83 vs 169.82 ± 37.82, p = 0.0001), and triglycerides (136.47 ± 36.4 vs 104.89 ± 22.15, p = 0.0001), and longer duration of Psoriasis and PsA. The serum uric acid levels were significantly positively correlated with age, duration of Psoriasis, duration of PsA, BMI, CRP, ESR, DAPSA, and PASI score. Multivariate analysis showed that male sex, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients.</p><p><strong>Conclusion: </strong>Psoriatic arthritis patients with hyperuricemia have higher age, BMI, disease activity, and more associated comorbidities. In PsA patients, hyperuricemia was associated with male sex, BMI, and increased disease activity, but not associated with PASI score. Key Points • Psoriasis, PsA, and hyperurice s is a bi-centric case-control retrospective of cardiovascular disease. • Male gender, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients. • Psoriatic arthritis patients with hyperuricemia have been more associated with comorbidities.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hyperuricemia in psoriatic arthritis: clinical correlations and implications.\",\"authors\":\"Samar AbdAlhamed Tabra, Hany M Aly, Saad Ghanem, Mohammed Hassan Abu-Zaid\",\"doi\":\"10.1007/s10067-025-07400-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Psoriatic arthritis (PsA) patients may have elevated serum uric acid levels, and hyperuricemia may impact the degree of inflammation and clinical disease severity.</p><p><strong>Objectives: </strong>comparison between PsA patients with and without hyperuricemia and assessment of the effect of hyperuricemia on clinical presentation, disease activity, disease severity, and associated comorbidities in PsA patients.</p><p><strong>Methods: </strong>76 PsA patients with hyperuricemia and 74 PsA patients with normal uric acid as control were included. Demographic, clinical, comorbidities, and laboratory data were collected. Hyperuricemia threshold ≥ 60 mg/L.</p><p><strong>Results: </strong>There were no significant differences between patients with and without hyperuricemia regarding gender, PsA articular subtype, PASI score, and treatment received, while patients with hyperuricemia were older (40.47 ± 8.53 vs 34.59 ± 7.29, p = 0.0001), had more comorbidity, higher body mass index (BMI) (28.49 ± 2.07 vs 26.91 ± 1.63kg/m2, p = 0.0001), DAPSA score (16.75 ± 7.04 vs 9.32 ± 6.35, p = 0.0001), ESR (34.78 ± 7.12 vs 28.55 ± 8.97, p = 0.0001), CRP (11.42 ± 3.23 vs 8.68 ± 4.04, p = 0.0001), serum cholesterol (220.42 ± 46.83 vs 169.82 ± 37.82, p = 0.0001), and triglycerides (136.47 ± 36.4 vs 104.89 ± 22.15, p = 0.0001), and longer duration of Psoriasis and PsA. The serum uric acid levels were significantly positively correlated with age, duration of Psoriasis, duration of PsA, BMI, CRP, ESR, DAPSA, and PASI score. Multivariate analysis showed that male sex, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients.</p><p><strong>Conclusion: </strong>Psoriatic arthritis patients with hyperuricemia have higher age, BMI, disease activity, and more associated comorbidities. In PsA patients, hyperuricemia was associated with male sex, BMI, and increased disease activity, but not associated with PASI score. Key Points • Psoriasis, PsA, and hyperurice s is a bi-centric case-control retrospective of cardiovascular disease. • Male gender, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients. • Psoriatic arthritis patients with hyperuricemia have been more associated with comorbidities.</p>\",\"PeriodicalId\":10482,\"journal\":{\"name\":\"Clinical Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10067-025-07400-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07400-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:目的:比较有高尿酸血症和无高尿酸血症的 PsA 患者,评估高尿酸血症对 PsA 患者临床表现、疾病活动性、疾病严重程度和相关合并症的影响。收集了人口统计学、临床、合并症和实验室数据。高尿酸血症阈值≥60 mg/L:高尿酸血症患者与非高尿酸血症患者在性别、PsA 关节亚型、PASI 评分和接受的治疗方面无明显差异,而高尿酸血症患者年龄更大(40.47 ± 8.53 vs 34.59 ± 7.29,P = 0.0001),合并症更多,体重指数(BMI)更高(28.49 ± 2.07 vs 26.91 ± 1.63kg/m2,P = 0.0001),DAPSA 评分更高(16.75 ± 7.04 vs 9.32 ± 6.35,P = 0.0001)、血沉(34.78 ± 7.12 vs 28.55 ± 8.97,P = 0.0001)、CRP(11.42 ± 3.23 vs 8.68 ± 4.04,P = 0.0001)、血清胆固醇(220.42 ± 46.83 vs 169.82 ± 37.82,p = 0.0001)和甘油三酯(136.47 ± 36.4 vs 104.89 ± 22.15,p = 0.0001),以及牛皮癣和 PsA 病程较长。血清尿酸水平与年龄、银屑病病程、PsA 病程、体重指数、CRP、血沉、DAPSA 和 PASI 评分呈显著正相关。多变量分析表明,男性、体重指数和疾病活动度增加是预测 PsA 患者高尿酸血症的独立因素:结论:患有高尿酸血症的银屑病关节炎患者的年龄、体重指数(BMI)、疾病活动度和相关合并症都较高。在 PsA 患者中,高尿酸血症与男性性别、体重指数和疾病活动性增加有关,但与 PASI 评分无关。要点 - 银屑病、PsA 和高尿酸血症是一项心血管疾病的双中心病例对照回顾性研究。- 男性性别、体重指数和疾病活动增加是预测 PsA 患者高尿酸血症的独立因素。- 患有高尿酸血症的银屑病关节炎患者更容易合并其他疾病。
Hyperuricemia in psoriatic arthritis: clinical correlations and implications.
Background: Psoriatic arthritis (PsA) patients may have elevated serum uric acid levels, and hyperuricemia may impact the degree of inflammation and clinical disease severity.
Objectives: comparison between PsA patients with and without hyperuricemia and assessment of the effect of hyperuricemia on clinical presentation, disease activity, disease severity, and associated comorbidities in PsA patients.
Methods: 76 PsA patients with hyperuricemia and 74 PsA patients with normal uric acid as control were included. Demographic, clinical, comorbidities, and laboratory data were collected. Hyperuricemia threshold ≥ 60 mg/L.
Results: There were no significant differences between patients with and without hyperuricemia regarding gender, PsA articular subtype, PASI score, and treatment received, while patients with hyperuricemia were older (40.47 ± 8.53 vs 34.59 ± 7.29, p = 0.0001), had more comorbidity, higher body mass index (BMI) (28.49 ± 2.07 vs 26.91 ± 1.63kg/m2, p = 0.0001), DAPSA score (16.75 ± 7.04 vs 9.32 ± 6.35, p = 0.0001), ESR (34.78 ± 7.12 vs 28.55 ± 8.97, p = 0.0001), CRP (11.42 ± 3.23 vs 8.68 ± 4.04, p = 0.0001), serum cholesterol (220.42 ± 46.83 vs 169.82 ± 37.82, p = 0.0001), and triglycerides (136.47 ± 36.4 vs 104.89 ± 22.15, p = 0.0001), and longer duration of Psoriasis and PsA. The serum uric acid levels were significantly positively correlated with age, duration of Psoriasis, duration of PsA, BMI, CRP, ESR, DAPSA, and PASI score. Multivariate analysis showed that male sex, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients.
Conclusion: Psoriatic arthritis patients with hyperuricemia have higher age, BMI, disease activity, and more associated comorbidities. In PsA patients, hyperuricemia was associated with male sex, BMI, and increased disease activity, but not associated with PASI score. Key Points • Psoriasis, PsA, and hyperurice s is a bi-centric case-control retrospective of cardiovascular disease. • Male gender, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients. • Psoriatic arthritis patients with hyperuricemia have been more associated with comorbidities.
期刊介绍:
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.